Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, outlines neoadjuvant chemoimmunotherapy for early triple-negative breast cancer. Specifically discussed is the KEYNOTE-522 trial (NCT03036488), the I-SPY trial (NCT01042379). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
